Press "Enter" to skip to content

New patent for NOVO drug RYBELSUS

0
Copyright © DrugPatentWatch. Originally published at New patent for NOVO drug RYBELSUS

Annual Drug Patent Expirations for RYBELSUS
Annual Drug Patent Expirations for RYBELSUS

Rybelsus is a drug marketed by Novo and is included in one NDA. It is available from one supplier. There are six patents protecting this drug.

RYBELSUS drug price trends.

This drug has one hundred and eleven patent family members in twenty-eight countries.

The generic ingredient in RYBELSUS is semaglutide. One supplier is listed for this compound. Additional details are available on the semaglutide profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent for NOVO drug RYBELSUS
    Get the DrugPatentWatch Daily Briefing

    ✓ Patent Expirations and Generic Entry

    ✓ Insightful Articles & Case Studies

    ✓ Patent Litigation & Challenges

    ✓ 505(b)(2) & Biosimilars

    ✓ Industry Trends

    DrugPatentWatch - Make Better Decisions